Celon Pharma S.A. (WSE: CLN)

Market Cap	1.35B
Revenue (ttm)	209.54M
Net Income (ttm)	18.51M
Shares Out	53.86M
EPS (ttm)	0.35
PE Ratio	71.69
Forward PE	24.51
Dividend	0.08 (0.32%)
Ex-Dividend Date	Jun 27, 2024

Volume	10,701
Average Volume	21,236
Open	25.30
Previous Close	25.30
Day's Range	24.85 - 25.35
52-Week Range	14.62 - 32.90
Beta	0.78
RSI	41.56
Earnings Date	Apr 16, 2025

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 515
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2023, Celon Pharma's revenue was 213.92 million, an increase of 10.33% compared to the previous year's 193.89 million. Losses were -28.12 million, -28.40% less than in 2022.